Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

Panelists discuss the key disease and patient factors considered when choosing between triplet and quadruplet induction regimens for patients with transplant-ineligible multiple myeloma, as well as the unmet needs that persist in the treatment landscape for both transplant-eligible and ineligible populations.

EP: 1.Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

EP: 2.Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

EP: 3.Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

EP: 4.MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

EP: 5.Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

Now Viewing

EP: 6.Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

EP: 7.Considerations for Use of CAR T-cell Therapy in Multiple Myeloma

EP: 8.CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024

EP: 9.Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers

EP: 10.Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life

1. Dr Ajai Chari to Dr Callander: What factors (disease or patient) do you consider when deciding between a triplet vs quadruplet induction regimen for those who are transplant ineligible?
2. Dr Ajai Chari to Dr Raje: What unmet needs still exist in the treatment paradigm of newly diagnosed multiple myeloma, both transplant eligible and ineligible?

Related Videos